|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||20.90 - 22.45|
|52 Week Range||20.90 - 76.90|
|Beta (5Y Monthly)||1.91|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.71|
Subscribe to Yahoo Finance Plus to view Fair Value for EDITLearn more
The 800+ hedge funds and famous money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30th. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund portfolios. Our extensive […]
If you want to know who really controls Editas Medicine, Inc. ( NASDAQ:EDIT ), then you'll have to look at the makeup...
Shares of Editas Medicine (NASDAQ: EDIT) were tumbling 13% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence. Editas Medicine CEO James Mullen specifically mentioned base editing in his comments at the J. P. Morgan conference and seemed a bit defensive.